Mwemezi Oswin, Ruggajo Paschal, Mngumi Jonathan, Furia Francis F
School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Renal Unit, Muhimbili National Hospital, Dar es Salaam, Tanzania.
Int J Nephrol. 2020 Oct 8;2020:8378947. doi: 10.1155/2020/8378947. eCollection 2020.
HIV-associated renal dysfunction is common among infected patients; the growing burden of this condition may be partly accounted for by improved survival attributed to sustained viral suppression with antiretroviral therapies (ART). Some ART regimens are nephrotoxic and may potentially contribute to renal dysfunction observed in these patients. This study aimed at investigating the prevalence of renal dysfunction among people living with HIV (PLHIV) on ART attending the care and treatment clinic (CTC).
A cross-sectional study was conducted between June and October 2019 among adults living with HIV on ART for 6 months or more attending CTC at Muhimbili National Hospital in Dar es Salaam, Tanzania. A total of 287 participants were screened for proteinuria and microalbuminuria using the Cybow 300 urine analyzer. Serum creatinine was tested for all participants, and it was used to estimate glomerular filtration rate (eGFR) using the CKD-EPI formula.
Out of 287 participants (72.1% female, mean age ± SD: 46.7 ± 10.6 years), about one-third (32.8%) had eGFR less than 90 ml/min, whereas 7% had eGFR less than 60 ml/min. Microalbuminuria and proteinuria were detected in 38.6% and 25.1% of participants, respectively. In the multivariate analysis, predictive determinants for renal dysfunction were higher viral loads (OR 2.5 (1.1-5.8), =0.031), diabetes mellitus (OR 5.5 (1.6-18.6), =0.006), and age above 60 years (OR 2.8 (1.0-7.3), =0.041); however, this was not the case for serum CD4 counts (OR 1.25 (0.7-2.3), =0.46).
High prevalence of renal dysfunction among PLHIV on ART was noted in this study. Viral loads above 1000 cp/ml and diabetes mellitus were noted to be associated with increased risk for renal dysfunction.
HIV 相关肾功能障碍在感染患者中很常见;这种情况负担的增加可能部分归因于抗逆转录病毒疗法(ART)持续抑制病毒使患者生存率提高。一些 ART 方案具有肾毒性,可能是导致这些患者出现肾功能障碍的原因之一。本研究旨在调查在接受治疗和护理门诊(CTC)治疗的接受 ART 的 HIV 感染者(PLHIV)中肾功能障碍的患病率。
2019 年 6 月至 10 月期间,在坦桑尼亚达累斯萨拉姆的穆希姆比利国家医院对接受 ART 治疗 6 个月或更长时间的成年 HIV 感染者进行了一项横断面研究。使用 Cybow 300 尿液分析仪对总共 287 名参与者进行蛋白尿和微量白蛋白尿筛查。对所有参与者检测血清肌酐,并使用 CKD-EPI 公式估算肾小球滤过率(eGFR)。
在 287 名参与者中(72.1%为女性,平均年龄±标准差:46.7±10.6 岁),约三分之一(32.8%)的 eGFR 低于 90 ml/分钟,而 7%的 eGFR 低于 60 ml/分钟。分别在 38.6%和 25.1%的参与者中检测到微量白蛋白尿和蛋白尿。在多变量分析中,肾功能障碍的预测决定因素是病毒载量较高(比值比 2.5(1.1 - 5.8),P = 0.031)、糖尿病(比值比 5.5(1.6 - 18.6),P = 0.006)和年龄超过 60 岁(比值比 2.8(1.0 - 7.3),P = 0.041);然而,血清 CD4 计数并非如此(比值比 1.25(0.7 - 2.3),P = 0.46)。
本研究发现接受 ART 的 PLHIV 中肾功能障碍的患病率较高。病毒载量高于 1000 cp/ml 和糖尿病与肾功能障碍风险增加有关。